Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4473-4485

  Zhang, Yifei ^a   Huang, Yixian ^a   Zhang, Peng ^a   Gao, Xiang ^a   Gibbs, Robert B ^a   Li, Song ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cancer therapy; Cellular uptake; Liposomes; SV119; Targeted delivery

Indexed keywords

ASPARTIC ACID; DOXORUBICIN; LIPOSOME; MACROGOL; SIGMA RECEPTOR LIGAND; SV119; UNCLASSIFIED DRUG;

ARTICLE; BRONCHUS MUCOSA; CANCER CELL; CANCER CELL DESTRUCTION; CELL STRAIN MCF 7; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DRUG DELIVERY SYSTEM; DRUG TUMOR LEVEL; DRUG UPTAKE; ENCAPSULATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; LUNG CARCINOMA; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PROSTATE ADENOCARCINOMA; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; AZABICYCLO COMPOUNDS; CARBAMATES; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; HUMANS; LIGANDS; LIPOSOMES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RECEPTORS, SIGMA; RHODAMINES;

EID: 84870380393     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S31981     Document Type: Article

References (31)

1. Wang AZ, Gu F, Zhang L, etal. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther. 2008;8(8): 1063-1070.
2. Wang X, Li J, Wang Y, etal. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano. 2012; 5(8):6184-6194.
3. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1995;1233(2): 134-144.
4. Moffatt S, Papasakelariou C, Wiehle S, Cristiano R. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591//PEI//DNA molecular conjugate. Gene Ther. 2006;13(9): 761-772.
5. Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies. Eur J Pharm Biopharm. 2010;74(3):467-473.
6. Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther. 2009;124(2):195-206.
7. Cobos EJ, Entrena JM, Nieto FR, Cendan CM, Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol. 2008;6(4):344-366.
8. John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res. 1999;59(18): 4578-4583.
9. John CS, Bowen WD, Saga T, etal. A malignant-melanoma imaging agent-synthesis, characterization, in-vitro binding and biodistribution of Iodine-125-(2-piperidinylaminoethyl)4-Iodobenzamide. J Nucl Med. 1993;34(12):2169-2175.
10. Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer. 2004;112(4):693-700.
11. Nakagawa O, Ming X, Huang L, Juliano RL. Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc. 2010;132(26):8848-8849.
12. Li SD, Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm. 2006; 3(5):579-588.
13. Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther. 2008;16(5): 942-946.
14. Mukherjee A, Prasad TK, Rao NM, Banerjee R. Haloperidol-associated stealth liposomes: a potent carrier for delivering genes to human breast cancer cells. J Biol Chem. 2005;280 (16):15619-15627.
15. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor-cell lines. Cancer Res. 1995;55(2):408-413.
16. Wheeler KT, Wang LM, Wallen CA, etal. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer. 2000;82(6): 1223-1232.
17. Matsumoto RR. Sigma receptors: historical perspective and background. In: Matsumoto RR, Bowen WD, Su TP, editors. Sigma Receptors: Chemistry, Cell Biology and Clinical Implications. New York: Springer; 2007:1-24.
18. Mach RH, Smith CR, AlNabulsi I, Whirrett BR, Childers SR, Wheeler KT. Sigma-2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res. 1997;57(1):156-161.
19. Colabufo NA, Berardi F, Contino M, etal. Correlation between sigma2 receptor protein expression and histopathologic grade in human bladder cancer. Cancer Lett. 2006;237(1):83-88.
20. Kashiwagi H, McDunn JE, Simon PO, etal. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer. 2007;6:48.
21. Spitzer D, Simon PO, Kashiwagi H, etal. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling. Cancer Res. 2011;72(1):201-209.
22. Di Paolo D, Pastorino F, Brignole C, etal. Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment. Tumori. 2008;94(2):246-253.
23. Vangveravong S, Xu J, Zeng C, Mach RH. Synthesis of N-substituted 9-azabicyclo[3.3.1] nonan-3α-yl carbamate analogs as σ2 receptor ligands. Bioorg Med Chem. 2006;14(20):6988-6997.
24. Eliaz RE, Szoka FC Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001;61(6):2592-2601.
25. Mach RH, Wheeler KT. Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo. Cent Nerv Syst Agents Med Chem. 2009;9(3):230-245.
26. Xu J, Zeng C, Chu W, etal. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun. 2011;2:380.
27. Spitzer D, Simon PO, Kashiwagi H, etal. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling. Cancer Res. 2012;72(1):201-209.
28. Lasic DD, Martin FJ, editors. Stealth Liposomes. Boca Raton: CRC Press; 1995.
29. Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer-chemotherapy. Adv Drug Deliv Rev. 1995; 16(2-3):285-294.
30. Zhou W, Yuan X, Wilson A, etal. Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug Chem. 2002;13(6):1220-1225.
31. Wang Y, Xu J, Xia X, etal. SV119-gold nanocage conjugates: a new platform for targeting cancer cells via sigma-2 receptors. Nanoscale. 2012;4(2):421-424.